Company / R&D per Share
ADMA Biologics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.02
FY2025
5-year range
$0.01 / $0.03
FY2021-FY2025
Trend
+150.9%
vs FY2024
Sector context
#203 of 208
Health Care
What the data says
Among 208 Health Care companies, ADMA Biologics, Inc. is in the bottom 2% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $0.01 in FY2022 to $0.72 in FY2016.
Based on SEC 10-K filings.
0.02 in FY2025 with a 5-year CAGR of -27.4%.
Improved from $0.01 to $0.02 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +38.0%
- 5-Year CAGR
- -27.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 208This company $0.02 Sector average $12.19
▼
-99.8% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 150.9% year-over-year.
- Ranks #203 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2016.
- Lowest r&d per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.02 | +150.9% |
| FY2024 | $0.01 | -46.1% |
| FY2023 | $0.01 | +94.2% |
| FY2022 | $0.01 | -78.0% |
| FY2021 | $0.03 | -65.1% |
| FY2020 | $0.10 | +361.6% |
| FY2019 | $0.02 | -79.8% |
| FY2018 | $0.11 | -82.1% |
| FY2017 | $0.60 | -16.9% |
| FY2016 | $0.72 | -29.9% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026